ArticleACS omega2025
Amiodarone and Ravuconazole Combination Potentiates Chemotherapy against Drug-Resistant Trypanosoma cruzi Strains.
Article in ACS omega, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Transcriptomic and ultrastructural responses to Amiodarone-Itraconazole in naturally benznidazole-resistant and -susceptible Trypanosoma cruzi strains.PLoS neglected tropical diseases · 2026Article
- Neurochagas: Experimental and human literature of an uncommon entity (Review).Medicine internationalReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Drug combinations represent valuable opportunities for developing more effective and safer treatments for Chagas disease. In this study, we investigated the effects of ravuconazole and amiodarone combinations against Trypanosoma cruzi infection. After ruling out antagonistic effects and increased cytotoxicity in vitro, a short-term in vivo protocol was used to evaluate parasitemia, immune response, and heart damage caused by the Y and Colombian T. cruzi strains in BALB/c and Swiss mice. Untreated mice displayed elevated parasitemia and pro-inflammatory cytokine levels, with strain-specific differences in IL-10 levels and the presence of parasites in the myocardium. Amiodarone monotherapy failed to exhibit in vivo anti-T. cruzi activity. While ravuconazole monotherapy at a subtherapeutic dose reduced parasitemia in all treated animals, its effects on the host response varied depending on the mouse and parasite strain, demonstrating greater activity in Swiss mice infected with the Y strain. Remarkably, amiodarone enhanced ravuconazole efficacy as combination chemotherapy was more effective than monotherapy in downregulating parasite load and pro-inflammatory cytokine levels, attenuating cardiac damage in all experimental models. These findings demonstrate a positive in vivo interaction between ravuconazole and amiodarone against T. cruzi infection. Furthermore, they highlight the relevance of the host genetic background and parasite strain on treatment outcomes.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.